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ABSTRACT: Immobilization of growth factors in scaﬀolds is important for controlling their dose and bioactivity for
regenerative medicine applications. Although numerous covalent and noncovalent immobilization strategies have been proposed,
better growth factor loading and dose control inside the scaﬀold is necessary. Nature of the binding site on the growth factor
interacting with scaﬀold is critical for preserving and achieving maximal growth factor functionality, which has been a relatively
less emphasized issue in previous studies. We recently reported heparin mimetic peptide nanoﬁbers, which mimic chemistry of
heparan sulfates. Heparin mimetic nanoﬁbers were shown to bind to vascular endothelial growth factor (VEGF) and direct
endothelial cells to angiogenesis. Here, we further investigated interactions between heparin mimetic peptide nanoﬁbers and
growth factors. We tested bioactivity of the nanoﬁber bound growth factors in order to understand the potential use of these
peptide nanoﬁber scaﬀolds as analogues of heparan sulfates. We observed that heparin mimetic peptide nanoﬁbers demonstrate
better binding proﬁles to VEGF, hepatocyte growth factor (HGF), and ﬁbroblast growth factor-2 (FGF-2) than control peptide
nanoﬁbers. We also identiﬁed that the heparin-binding domain of VEGF is critical for its interaction with these nanoﬁbers.
However, the heparin-binding site is not indispensable for binding of all growth factors to nanoﬁbers. We also showed that
binding of growth factors to nanoﬁbers does not cause any loss in bioactivity through in vitro cell culture assays with PC-12 cells.
These results reveal that heparin mimetic peptide nanoﬁbers can eﬀectively mimic heparan sulfates in extracellular matrix and
provide an optimal milieu for spatial presentation of important growth factors. These properties make peptide nanoﬁber scaﬀolds
promising materials for regenerative medicine applications through eﬃcient and precisely controlled growth factor delivery.
1. INTRODUCTION
Functional biomaterials can aid eﬀorts to control cell behavior
and promote tissue regeneration. New-generation biomaterials
diﬀer from conventional ones in terms of controlling dose and
bioactivity of delivered molecules (e.g., growth factors) more
precisely rather than acting as mere scaﬀolds.1 Immobilization
of growth factors either covalently or noncovalently to a
scaﬀold provides spatial distribution of growth factors inside the
scaﬀold. Although covalent immobilization enables prolonged
release of growth factors, speciﬁcity of coupling site on the
growth factors is diﬃcult to achieve, and proteins may lose their
bioactivity during coupling process.2 Materials can also be
programmed to interact with growth factors through decoration
of speciﬁc binding sites that interact with growth factors
noncovalently. This type of interaction is predominant in
nature. For example, heparan sulfate proteoglycans in
extracellular matrix bind to heparin-binding growth factors
mainly through electrostatic interactions.3 Binding to heparan
sulfates is critical for growth factor signaling, protection from
degradation, and local accumulation of growth factors in the
vicinity of cells.
Maximal dose of growth factors that can be loaded onto
materials correlates with the amount of growth factor binding
epitopes on the scaﬀolds. Designing bioactive scaﬀolds that can
present the maximum number of epitopes while enabling
control over epitope number would be beneﬁcial for
regenerative medicine applications. Several strategies for
designing growth factor binding scaﬀolds were previously
proposed. Sulfated alginate hydrogels, inspired from sulfated
characteristics of glycosaminoglycans (e.g., heparan sulfate),
showed superior aﬃnity to heparin-binding growth factors
relative to that of bare alginate.4 Fibrin matrices functionalized
with 12−14 type three repeats of ﬁbronectin, which non-
selectively interact with various growth factors, performed as an
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eﬃcient growth factor delivery system, intensifying growth
factor bioactivity in vitro.5 However, the relatively larger
meshwork size of these polymeric scaﬀolds limits the density of
epitope presentation. Moreover, epitope concentration on a
polymer chain should be determined before synthesis. On the
other hand, peptide amphiphiles, which are small building
blocks, can be triggered to form supramolecular assemblies
such as high-aspect-ratio nanoﬁbers in a controlled manner.6
Nanoscale properties maximize epitope density, while epitope
concentration can be controlled via epitope dilution before
inducing nanoﬁber formation.7 For example, heparin-binding
PAs formed nanoﬁber scaﬀolds when mixed with heparin,
where heparin was used to bind to growth factors inside the
scaﬀold.8 This system induced in vivo angiogenesis more
eﬃciently than standard scaﬀolds. However, since long-chain
heparin was used as the growth factor binding ligand, epitope
dilution was limited. Moreover, contaminants in heparin
batches have been reported to induce side eﬀects in humans.9
Considering these issues, we recently designed a heparin
mimetic PA (HM-PA) molecule, which bears key functional
groups present in heparin and can be readily induced to form
nanoﬁber scaﬀolds for regenerative medicine applications.10 We
have shown that these nanoﬁbers bind vascular endothelial
growth factor (VEGF) and induce in vitro and in vivo
angiogenesis eﬃciently. The arrangement of functional groups
on HM-PA/K-PA nanoﬁbers is suﬃcient to bind other heparin-
binding growth factors and in a manner that would elevate the
bioactivity of these growth factors. In this work, we studied the
interactions of heparin mimetic peptide nanoﬁbers with various
growth factors and the bioactivity of nanoﬁber−growth factor
complexes. This study presents the high potential of heparin
mimetic peptide nanoﬁbers in binding various heparin-binding
growth factors, which are widely used in regenerative medicine
and in directing cellular activity.
2. MATERIALS AND METHODS
Materials. 9-Fluorenylmethoxycarbonyl (Fmoc) and tert-butox-
ycarbonyl (Boc) protected amino acids, [4-[α-(20,40-dimethoxyphen-
yl) Fmoc-aminomethyl] phenoxy] acetamidonorleucyl-MBHA resin
(Rink amide MBHA resin), Fmoc-Asp(OtBu)-Wang resin, and 2-(1H-
benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate
(HBTU) were purchased from NovaBiochem and ABCR. The other
chemicals for PA synthesis were purchased from Fisher, Merck, Alfa
Aesar, or Aldrich. All chemicals were used as provided. Heparin and
chondroitin sulfate were purchased from Sigma-Aldrich. ELISA
reagents were obtained from Invitrogen. Paired antibodies for diﬀerent
growth factors were purchased from R&D, except for VEGF
(Invitrogen). Gold-attached secondary antibody (Aurion Immunogold
reagent) was obtained from Electron Microscopy Sciences. Growth
factors were obtained from e-bioscience (VEGF121, HGF, FGF-2,
BMP-2), Invitrogen (VEGF165), and Sigma-Aldrich (NGF).
Peptide Synthesis. HM-PA and Lauryl-VVAGK-Am (K-PA) were
constructed on Rink Amide MBHA resin, while Lauryl-VVAGE-Am
(E-PA) was constructed on Fmoc-Asp(OtBu)-Wang resin (Figure S1,
Supporting Information). Amino acid couplings were performed with
2 equiv of Fmoc-protected amino acid, 1.95 equiv of HBTU, and 3
equiv of N,N-diisopropylethylamine (DIEA) for 2 h. To remove the
Fmoc group, 20% (v/v) piperidine/dimethylformamide solution
(DMF) was added for 20 min. To block the remaining free amine
groups after amino acid coupling, 10% (v/v) acetic anhydride solution
in DMF was used (30 min). After each step, the resin was washed by
using DMF, dichloromethane (DCM), and DMF (three times each).
To synthesize HM-PA, sulfobenzoic acid was added to the side chain
of lysine. A lysine residue with 4-methytrityl (Mtt) side-chain
protection was used for selective deprotection of amine groups.
Resins were treated with a TFA/TIS/H2O/DCM mixture
(5:2.5:2.5:90 ratio; TFA = triﬂuoroacetic acid; TIS = triisopropyl
Figure 1. Nanoﬁber formation mechanism. Negatively charged HM-PA, E-PA, or heparin was mixed with positively charged K-PA to form respective
nanoﬁbers. Tiny spheres on nanoﬁbers depict functional groups (red - sulfonate; green - hydroxyl; blue - carboxylate). Dashed red line indicates
heparin. After nanoﬁber formation, heparin and functional groups of PAs are assumed to be presented by nanoﬁbers into surrounding aqueous
media. Density of heparin and functional groups of HM-PA on PA nanoﬁbers do not reﬂect actual density; schematic images are used for
representative purposes.
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silane) for 5 min to remove Mtt. To cleave PAs from the resin, TFA/
TIS/H2O mixture (95:2.5:2.5 ratio) was treated with resin for 2 h.
Excess TFA was removed by rotary evaporation. The remaining
viscous PA solution was triturated with ice-cold ether, and the
resulting white precipitate was dissolved in aqueous solution and
freeze-dried. PAs were characterized by liquid chromatography and
mass spectrometry (LC-MS). Mass spectrum was obtained with
Agilent 1200 LC-MS equipped with Agilent 6530 Q-TOF with an ESI
source and Zorbax Extend-C18 2.1 × 50 mm column for basic
conditions and Zorbax SB-C8 4.6 mm × 100 mm column for acidic
conditions. A gradient of (a) water (0.1% (v/v) formic acid or 0.1%
(v/v) NH4OH) and (b) acetonitrile (0.1% (v/v) formic acid or 0.1%
(v/v) NH4OH) was used. An Agilent 1200 preparative reverse-phase
HPLC system equipped with a Zorbax Extend-C18 21.2 × 150 mm
column for basic conditions and a Zorbax SB-C8 21.2 × 150 mm
column for acidic conditions was used to purify the peptides. A
gradient of (a) water (0.1% (v/v) TFA or 0.1% (v/v) NH4OH) and
(b) acetonitrile (0.1% (v/v) TFA or 0.1% (v/v) NH4OH) was used.
Nanoﬁber Formation Mechanism. Nanoﬁber formation mech-
anisms were based on mixing oppositely charged PAs, which
neutralized net charge on each other and induced self-assembly to
higher-order nanoﬁbers. Three diﬀerent types of nanoﬁbers were used
in this study (Figure 1). Bioactive HM-PA nanoﬁber was prepared
similarly to our previous work.10 HM-PA (−3 charge) and K-PA (+1
charge) were mixed in a 1:2 molar ratio for HM-PA/K-PA nanoﬁbers,
while E-PA (−2 charge) and K-PA (+1 charge) were mixed in a 1:1
molar ratio for control E-PA/K-PA nanoﬁbers, to render both
nanoﬁbers negatively charged. Since the K-PA amount is lower for
E-PA/K-PA nanoﬁbers than HM-PA/K-PA nanoﬁbers in this case, we
used E-PA/K-PA 2x nanoﬁbers as a control for this issue. For E-PA/K-
PA 2x nanoﬁbers, we used both E-PA and K-PA in doubled
concentrations but same molar ratio (1:1). Heparin carrying
nanoﬁbers were also prepared by mixing heparin and K-PA as in
our previous work,10 while the weight ratio was 1:2 (heparin to K-PA)
in this work. Heparin/K-PA nanoﬁbers were used as a positive control.
All PAs used for nanoﬁber formation were at pH 7.
ELISA-Based Binding Assay. ELISA technique was exploited to
compare binding levels of growth factors to HM-PA/K-PA nanoﬁbers
and control nanoﬁbers (Figure 1). MaxiSorp plates (Thermo
Scientiﬁc, NUNC) were coated with PA nanoﬁbers or blank solution
overnight at 4 °C. The PA nanoﬁber formation was performed on
plates by mixing negatively and positively charged PAs. Brieﬂy, 0.05%
HM-PA/0.05% K-PA, 0.025% E-PA/0.025% K-PA, 0.05% E-PA/
0.05% K-PA, or 0.05% heparin/0.1% K-PA (all are w/v) equal volume
mixtures were prepared. The next day, the solutions were removed and
the wells were washed with washing buﬀer (Tween 20 in 0.9% (w/v)
NaCl solution, pH = 7.4). These plates are high-aﬃnity binding plates
for a broad range of molecules with hydrophobic/hydrophilic
character, thus, even after extensive washing, plates were observed to
be coated completely with PA nanoﬁbers (Figure S3). After tapping
for drying, blocking buﬀer was added. This was followed by the
addition of growth factor solution, biotinylated antibody against
growth factor, streptavidin-linked horseradish peroxidase (HRP) and
HRP substrate (3,3′,5,5′-tetramethylbenzidine (TMB)). After 15−20
min of incubation, the reaction was stopped with sulfuric acid.
Absorbance change due to color formation was measured by a
Spectramax M5 microplate reader (Molecular Devices) at 450 nm
wavelength. This value was subtracted from the reference value (650
Figure 2. TEM images of immunogold stained HGF on HM-PA/K-PA nanoﬁbers. (a) HGFs were observed on both individual nanoﬁbers and PA
aggregates. White dots indicate gold nanoparticles. (b) Inverted image, gold nanoparticles were visualized as black dots. (c) Magniﬁed version of an
individual nanoﬁber shown in image a, presenting gold nanoparticles. (d) Negative control (without primary antibody) shows no staining.
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nm). All treatments were performed with three replicates and are
shown as mean ± standard deviation. Experiments were repeated at
least two times independently. For statistical analysis, two-way
ANOVA with Bonferroni posthoc analysis (Figure 2a) and Student’s
t test (Figure 2b,c) were used.
Atomic Force Microscopy (AFM) Imaging. AFM imaging was
performed to determine the coating eﬃciency of PA nanoﬁbers on
ELISA plates. Coating was performed similarly to “ELISA-binding
assay” procedures. After overnight incubation of plates with PA
nanoﬁber solution, the solution was aspirated and the plate was
washed 2−3 times with ELISA washing buﬀer (Tween 20 in 0.9% (w/
v) NaCl solution, pH = 7.4). The plates were dried by tapping, and the
coated bottom part was removed for AFM imaging. Bare ELISA plates
were also imaged with AFM to understand their surface roughness.
Non-contact-mode AFM was performed by using model MFP-30 from
Asylum Research. All images were taken with a 0.5 Hz scan rate. Tips
with resonance frequency of 300 kHz and spring constant of 40 N/m
were used in all experiments (BudgetSensors).
Isothermal Titration Calorimetry (ITC). To investigate the
interaction between HM-PA/K-PA nanoﬁbers and VEGF121, we used
the iTC200 system (MicroCal, GE Healthcare). VEGF121 (0.27 mg/
mL in 1x PBS solution) was titrated into HM-PA/K-PA nanoﬁber
solution. For HM-PA/K-PA nanoﬁber solution, 0.04% HM-PA and
0.04% K-PA (both in H2O and w/v) were mixed to form nanoﬁbers in
solution, which was diluted 2-fold with 2x PBS to obtain HM-PA/K-
PA nanoﬁber solution in 1x PBS. Reaction was performed at 25 °C
with 500 rpm stirring speed. Twenty injections were performed, where
the injection period was 4 s and the space between injections was 150
s. All solutions that were used in ITC experiments were at pH 7.
Immunogold Staining and Transmission Electron Micros-
copy (TEM) Imaging. Hepatocyte growth factor (HGF) binding on
HM-PA/K-PA nanoﬁbers was visualized by using immunogold
staining and TEM imaging. First, HM-PA/K-PA gel was formed by
mixing 20 μL of 1% HM-PA with 1% K-PA (w/v). Gel was diluted 10
times, and 30 μL of the diluted solutions was dropped onto paraﬃn
ﬁlm. Cu grids were reversed onto these drops and incubated for 5 min.
The tiny amount of liquid left on the grids was absorbed with dust-free
paper, and the grids were dipped into 1x PBS solution two times to
wash weakly bound nanoﬁbers. Grids were reversed onto 30 μL of
blocking solution (Assay buﬀer, Invitrogen) and incubated for 1 h at
room temperature. Drops on grids were absorbed, and HGF (500 ng/
mL in assay buﬀer) was added onto the grids. After 2 h of incubation,
grids were washed with PBS ﬁve times. Primary antibody (25 μg/mL,
R&D) against human HGF was added onto grids and incubated
overnight at 4 °C. Grids were washed with PBS 5 times. Gold-attached
antibody (25 nm gold particles conjugated to antimouse IgG), 1/20
diluted from stock with assay buﬀer, was put onto paraﬃn ﬁlm, and
grids were reversed onto this solution, to prevent precipitation of gold
particles onto the grid surface due to gravitation. After 1 h, grids were
washed ﬁve times with PBS and three times with double-distilled water
(ddH2O). After drying at room temperature for at least 3 h, TEM
(FEI, Tecnai G2 F30) imaging was performed. All images were taken
in STEM mode with an HAADF (high angle annular dark ﬁeld)
detector.
HM-PA/K-PA Nanoﬁber versus Heparin Competition Assay.
HM-PA/K-PA nanoﬁber and heparin competition for the same site of
growth factor was studied by increasing doses of heparin (0.0003% to
0.3%, w/v) in the presence of various growth factors just before latter
ones were incubated with HM-PA/K-PA nanoﬁbers. HM-PA/K-PA
nanoﬁber coating and the rest of the assay was performed similarly to
ELISA-based binding assay. IC50 (half-maximal inhibitory concen-
tration) of heparin to inhibit growth factor and HM-PA/K-PA
nanoﬁber binding was calculated for each growth factor by using
GraphPad Prism software. Nonlinear regression analysis with robust
ﬁtting was carried out for this purpose. We performed the same
experiment with chondroitin sulfate instead of heparin (only for
ﬁbroblast growth factor-2 (FGF-2)) to understand the eﬀect of
heparin. All treatments were performed with three replicates and are
shown as mean ± standard deviation. Experiments were repeated
twice, independently.
NGF Induced Neurite Extension Assay. To determine biological
activity caused by interaction of PA nanoﬁbers with nerve growth
factor (NGF), PC-12 cells were cultured on NGF-coated PA nanoﬁber
surfaces. PA nanoﬁber gel scaﬀolds with −1 charge were prepared as
described below. For HM-PA/K-PA gel, 1.5 mM HM-PA was mixed
with 3 mM K-PA at equal volumes (40 μL for 96 well-plate). E-PA/K-
PA gel was formed in the same way by mixing 1.5 mM E-PA with 1.5
mM K-PA while E-PA/K-PA 2x gel was prepared by mixing 3 mM E-
PA with 3 mM K-PA. 0.1% (w/v) Poly-D-lysine (PDL) was coated as a
control since it is not expected to bind NGF due to its dense positive
charge. After gel formation, plates were dried under a laminar ﬂow
hood and UV sterilized. For NGF coating on PA coated surfaces, NGF
was added at concentrations of 10 ng/mL or 50 ng/mL. After 2 h of
incubation at room temperature, wells were washed three times with
PBS to remove any unbound NGF. PC-12 cells (5 × 103 cells/well)
were then seeded and cultured on these surfaces for 4 days. In another
experimental group, incubated NGF was not removed to test the eﬀect
of surface bound and soluble NGF at the same time (total
concentration was the same with other groups). In this case, cells
were added directly on NGF solution over PA or PDL coated surfaces.
For soluble NGF groups, the same concentration of NGF was added
on cells after seeding (n = 3 for all samples). At the end of 4 days,
images (5 images/well) were taken at 200x magniﬁcation, and neurite
lengths were quantiﬁed with Image J. For statistical analysis, two-way
ANOVA with Bonferroni posthoc analysis was performed (Figures 6
and S4).
For immunostaining, PA nanoﬁber coating was carried out by using
the same protocol except that PAs were coated on glass coverslips
placed in 24 well-plates (total volume: 300 μL/well). NGF coating (50
ng/mL) was performed as described above and 3 × 104 cells/well were
seeded. After 4 days of culture, cells were ﬁxed with 4%
paraformaldehyde, permeabilized with 0.3% TritonX-100, and blocked
with 10% goat serum. Antibodies against β-III-Tubulin (Millipore,
1:250 dilution) and synaptophysin 1 (Sigma-Aldrich, 1:400 dilution)
were incubated overnight at 4 °C. After washing, cells were incubated
with goat-antirabbit IgG-Cy3 (Chemicon, 1:200 dilution) and goat-
antimouse IgG-Cy2 (Chemicon, 1:400 dilution) for 1 h at room
temperature and washed to remove any unbound antibodies.
Table 1. Growth Factors Used in This Study
growth factor physiological functiona
heparin
aﬃnity
dissociation
constant (Kd)
b
vascular endothelial growth factor
(VEGF)
angiogenesis, vasculogenesis, endothelial cell growth and migration high
(VEGF165)
none
(VEGF121)
165 nM30
hepatocyte growth factor (HGF) cell motility, mitogenesis and matrix invasion high 12 nM30
ﬁbroblast growth factor-2 (FGF-2) migration, proliferation and survival of endothelial cells, inhibition of diﬀerentiation of
embryonic stem cells
high 23 nM30
39 nM31
bone morphogenetic protein-2
(BMP-2)
diﬀerentiation and migration of osteoblasts high 20 nM17
nerve growth factor (NGF) survival and diﬀerentiation of neural cells moderate not determined
aFunctions were reproduced from Lee et al.2 and NCBI. bDissociation constant of heparin−growth factor interaction.
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Coverslips were then removed from wells, mounted by using Prolong
gold antifade reagent (Invitrogen), and imaged with a confocal
microscope (Carl Zeiss, LSM510).
3. RESULTS AND DISCUSSION
3.1. HM-PA Nanoﬁbers Bind Heparin-Binding Growth
Factors with Strong Aﬃnity. Heparin-binding growth
factors that are widely used in regenerative medicine studies
were studied for testing the eﬃcacy of growth factor-binding
peptide nanoﬁbers (Table 1). Peptide molecules forming the
nanoﬁbers are depicted in Figure 1, and nanoﬁber formation
mechanisms are explained in the Materials and Methods
section. While forming nanoﬁbers, the ratio of negatively
charged PAs (HM-PA and E-PA) to positively charged K-PA in
nanoﬁbers is critical as it determines the net charge on
nanoﬁbers. Ratios of 1:2 and 1:1 for HM-PA/K-PA and E-PA/
K-PA were chosen, respectively, in order to render both
nanoﬁbers net one negative charge. The E-PA cannot retain its
negative charge at a higher ratio of K-PA (1:2) and loses its
capacity to hold growth factors (data not shown).
To validate and visualize growth factor−peptide nanoﬁber
interactions, we performed immunogold staining of growth
factors bound to the nanoﬁbers. For this experiment, we chose
HGF as the model growth factor. TEM was used to image the
complex of peptide nanoﬁbers and gold nanoparticle-
conjugated antibody against HGF. Both individual nanoﬁbers
(Figure 2a,c) and nanoﬁber aggregates (Figure 2a,b) were
observed to bind growth factors (white dots in a,c; black dots in
b). When primary antibody for growth factor was not used, no
growth factor binding was observed, excluding the possibility of
nonspeciﬁc binding of gold attached secondary antibodies to
nanoﬁbers (Figure 2d). Nanoﬁber aggregates bound to growth
factors in TEM imaging were studied by energy-dispersive X-
ray (EDX) analysis, and a strong sulfur signal caused by
sulfonate group of HM-PA (Figure S2) was observed
demonstrating the presence of peptide nanoﬁbers interacting
with the growth factor.
Growth factor−peptide nanoﬁber interaction was further
investigated in-depth to understand the eﬀect of heparin
mimicking functional groups (carboxylate, hydroxyl, and
sulfonate) on nanoﬁbers in growth factor binding. ELISA-
based growth factor binding assay was used to study the
binding mechanism. All three types of peptide nanoﬁbers were
coated eﬃciently onto an ELISA plate as revealed by AFM
imaging, which were clearly distinguishable in terms of
roughness compared to bare ELISA plate (Figure S3). After
conﬁrming the nanoﬁber coating on ELISA plates, growth
factors bound to the peptide nanoﬁbers were detected with
ELISA assay.
HM-PA nanoﬁbers were designed to mimic heparin and
showed a higher binding level to three growth factorsHGF,
VEGF, and FGF-2than control E-PA nanoﬁbers. This
diﬀerence conﬁrms that growth factor and nanoﬁber interaction
is further strengthened by additional functional groups on HM-
PA/K-PA nanoﬁbers (Figure 3). Heparin-carrying (heparin
with K-PA) nanoﬁbers, which were included as a positive
control, showed the strongest binding signal (Figure 3a).
Meanwhile, bare plate surface, which was the negative control,
showed the weakest signal (shown for VEGF165 in Figure 3a
and other growth factors in Figure S4). HM-PA/K-PA
nanoﬁbers showed a comparable level of binding to VEGF165
with heparin-carrying nanoﬁbers (Figure 3a). Nanoﬁber control
(E-PA/K-PA) showed signiﬁcantly less binding level to
VEGF165 compared to HM-PA/K-PA nanoﬁbers. An E-PA/K-
PA 2x sample containing two-folds higher control nanoﬁber
concentration was used to eliminate the eﬀect of incomplete
coverage of the surface on binding. There was no signiﬁcant
diﬀerence between E-PA/K-PA and E-PA/K-PA 2x samples,
indicating complete coverage and saturation of the surface with
one-fold control nanoﬁbers (Figure 3a).
Growth factor−peptide nanoﬁber interactions were analyzed
at two diﬀerent growth factor concentrations to investigate the
eﬀect of growth factor concentration on nanoﬁber binding.
VEGF165 and HGF showed higher level of binding to HM-PA/
K-PA nanoﬁbers than E-PA/K-PA nanoﬁbers for both 10 ng/
mL and 50 ng/mL growth factor concentrations (Figure 2b,c).
In addition, FGF-2 bound to HM-PA/K-PA nanoﬁbers
Figure 3. ELISA-based binding assay. (a) Binding levels of 10 ng/mL
or 50 ng/mL of VEGF165 with diﬀerent nanoﬁbers or PA-free surface
are shown. The diﬀerence between HM-PA/K-PA and other
treatments was signiﬁcant for both growth factor concentrations. (b)
Binding levels of diﬀerent growth factors (10 ng/mL) to HM-PA/K-
PA or E-PA/K-PA nanoﬁbers are compared. (c) Binding levels of
diﬀerent growth factors (50 ng/mL) to HM-PA/K-PA and E-PA/K-
PA nanoﬁbers are compared. ***p < 0.001, **p < 0.01, *p < 0.05, ns
= not signiﬁcant. Statistical analysis was performed with two-way
ANOVA with Bonferroni posthoc analysis (a) and Student’s t test (b
and c). Experiments were performed as three replicates (n = 3).
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signiﬁcantly more than control nanoﬁbers at higher growth
factor concentration (Figure 2c). In spite of its heparin-binding
property, BMP-2 exhibited a strong binding pattern to both
HM-PA/K-PA and control nanoﬁbers at both low and high
growth factor concentrations (Figures 2b and 2c). Negative
charge provided by carboxylate groups on control peptide
nanoﬁbers might be suﬃcient to bind to BMP-2 strongly,
leading to similar binding pattern of BMP-2 to E-PA/K-PA and
HM-PA/K-PA nanoﬁbers. However, the binding site of BMP-2
might diﬀer between HM-PA/K-PA and E-PA/K-PA nano-
ﬁbers, which could change its bioactivity.
One of the weakest binding patterns was observed with
NGF, where HM-PA/K-PA nanoﬁbers showed slightly better
binding at higher growth factor concentration. However, it was
clear that even this degree of binding makes a remarkable
diﬀerence in inducing cellular activity, which will be described
in more detail in the following sections (Figures 5−7).
VEGF121, which lacks heparin-binding domain, did not reveal
any binding signal to HM-PA/K-PA nanoﬁbers, while it
exhibited very weak binding to E-PA/K-PA nanoﬁbers. Thus,
heparin-binding domain of VEGF is critical for its binding to
HM-PA/K-PA nanoﬁbers. These results indicate that HM-PA/
K-PA nanoﬁbers with heparin mimicking functional groups
stand to be an excellent analogue for heparin regarding growth
factor binding capability.
3.2. Role of Heparin-Binding Domains of Growth
Factors in Their Interaction with HM-PA/K-PA Nano-
ﬁbers. While growth factor−nanoﬁber binding has been
emphasized in the literature, the binding site of growth factor
to material should also be taken into consideration when
designing biomaterials for regenerative medicine applications.
Growth factors interact with heparan sulfates through their
“heparin-binding domain”.11−17 Growth factor−heparan sulfate
binding induces dimerization/oligomerization of growth factor
receptors (generally tyrosine kinase receptors), which is
required for autophosphorylation of receptors and subsequent
activation of signaling pathways.18−20 For signaling to be
eﬀective, a threshold number of receptor-growth factor
complexes should be active on the surface of cells for an
appropriate period of time.21 This requires stability of growth
factor−receptor interactions, which are maintained by heparan
sulfates acting as coreceptors.21,22 Thus, a material designed to
mimic heparan sulfates should bind to growth factors through
their heparin-binding domains, which would prevent blocking
of other sites on growth factors such as “receptor binding site”
that is critical for signaling.
VEGF165 and VEGF121 exhibited signiﬁcantly diﬀerent
binding levels to HM-PA/K-PA nanoﬁbers in ELISA-based
binding assay. To clarify the necessity of heparin-binding
domain in HM-PA/K-PA nanoﬁber - growth factor interaction,
diﬀerential aﬃnity of VEGF165 and VEGF121 to HM-PA/K-PA
nanoﬁbers was further tested by using ITC. Previously, binding
constant between VEGF165 and HM-PA/K-PA nanoﬁbers was
measured by using this technique.10 Here, interaction between
VEGF121 and HM-PA/K-PA nanoﬁbers was investigated
through a similar protocol that we used in our previous
study.10 While the binding constant of HM-PA/K-PA−
VEGF165 was similar to the binding constant of heparin−
VEGF165,
10 VEGF121 revealed no binding signal with HM-PA/
K-PA, further supporting the critical contribution of the
heparin-binding domain in VEGF−HM-PA/K-PA nanoﬁber
interaction (Figure S5).
To understand the role of heparin-binding domains of other
growth factors in HM-PA/K-PA nanoﬁber binding, a
competition assay was performed, where heparin and HM-
PA/K-PA nanoﬁbers competed for binding to growth factors.
In this assay, growth factors bound to heparin were expected to
be washed away, while those that bound to HM-PA nanoﬁbers
were expected to stay in the plate and be detected with ELISA.
Thus, signal diminution in ELISA would indicate that both
heparin and HM-PA/K-PA nanoﬁbers compete for the same
binding site. In total agreement with previous assays, the
VEGF165 binding signal showed a very sharp decline as heparin
concentration was increased, further supporting that HM-PA/
K-PA nanoﬁbers compete for nonredundant heparin-binding
domain (Figure 4a). Interestingly, only FGF-2 showed a similar
pattern to VEGF165 among other growth factors (Figure 4).
The inhibitory eﬀect was speciﬁc to heparin, since chondroitin
sulfate (another sulfated glycosaminoglycan) was not able to
inhibit FGF-2 binding to HM-PA/K-PA nanoﬁbers (exhibited
only limited inhibitory eﬀect at maximal dose, Figure S6).
Heparin was more inhibitory at its minimal dose than
chondroitin sulfate at its maximal dose. Since heparan sulfate
(or heparin) binding is critical for bioactivity of VEGF165 and
Figure 4. Competition assay between heparin and HM-PA/K-PA
nanoﬁbers for growth factor binding. (a) Dose-dependent interference
of heparin with growth factor binding to HM-PA/K-PA nanoﬁbers.
For each growth factor, the binding signal to HM-PA/K-PA nanoﬁbers
when there was no heparin in milieu was taken as 100%. (b) IC50 value
of heparin for inhibiting HM-PA/K-PA nanoﬁber binding of each
growth factor was calculated and represented. Experiment was
performed as three replicates (n = 3).
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FGF-2,23,24 binding to the same site with heparin renders HM-
PA/K-PA nanoﬁbers a very eﬃcient scaﬀold for delivery of
these growth factors. Heparin-binding domains of HGF and
BMP-2 were more redundant than those of VEGF and FGF-2
in HM-PA/K-PA nanoﬁber binding (Figure 4a). IC50 for HGF
and BMP-2 calculated from competitive binding curves in
Figure 4a were nearly 10 times higher than IC50 of VEGF and
FGF-2 (Figure 4b). Dissociation constants of heparin and these
growth factors were shown to be similar to each other in the
literature (Table 1). Thus, the diﬀerence between IC50 values of
heparin between these two groups of growth factors cannot be
attributed to any diﬀerence in their aﬃnity to heparin. This
diﬀerence could be caused by the existence of extra binding
sites, other than the heparin-binding site, on BMP-2 and HGF
for HM-PA/K-PA nanoﬁber binding. NGF binding to heparin
is known to be moderate,25 compared to strong binding
aﬃnities of other growth factors, which may be the reason for
poor competition between heparin and HM-PA/K-PA nano-
ﬁbers for binding to NGF. Nonetheless, NGF seems to have
diﬀerent binding sites for HM-PA/K-PA nanoﬁbers and
heparin (Figure 4). IC50 of heparin for NGF was nearly 80
times higher than IC50 of heparin for VEGF/FGF-2 and 7−8
times higher than IC50 of heparin for HGF/BMP-2 (Figure 4b).
3.3. HM-PA/K-PA nanoﬁber - growth factor inter-
action is translated to cellular activity. As mentioned
above, improper interaction of materials with growth factors
(e.g., through improper binding site) can block growth factor
activity unexpectedly. Hence, growth factor’s biological
functionality should be validated after it is tethered on the
material. NGF, which had the weakest interaction among the
growth factors that were tested in this study and whose
heparin-binding domain was least required for HM-PA/K-PA
nanoﬁber binding, was selected for studying biological activity.
To investigate the eﬀect of HM-PA/K-PA nanoﬁber binding on
NGF functionality, neurite outgrowth by PC-12 cells cultured
on NGF-coated PA nanoﬁber surfaces was analyzed. NGF
retained its ability to induce neurite outgrowth fully when it was
bound to HM-PA/K-PA nanoﬁbers. Neurite outgrowth
performances of PC-12 cells did not deteriorate when NGF
was presented to cells as coated on nanoﬁbers compared to its
soluble form (Figure 5). To exclude any possibility of
bioactivity reduction due to diﬀerential amount of growth
factors between “soluble” and “coated” treatments, unbound
growth factors in “coated” treatment were not removed and
stayed in solution. Considering that the total growth factor
amount was same in both “soluble” and “coated” treatments,
HM-PA/K-PA nanoﬁbers enhanced NGF signaling, since
neurite outgrowth activity in “coated” samples was signiﬁcantly
higher than “soluble” samples (Figure 5a) in the presence of
low growth factor concentration. No signiﬁcant increase in
bioactivity was observed at higher growth factor concentration
(Figure 5b). This diﬀerence could be due to the fact that higher
concentration of growth factors in the vicinity of cells did not
necessitate their accumulation and preservation with HM-PA/
K-PA nanoﬁbers for cellular activity. Interestingly, we did not
observe such a diﬀerence with E-PA/K-PA nanoﬁbers,
indicating contribution of functional groups on HM-PA/K-PA
nanoﬁbers for NGF signaling. Moreover, higher binding of
HM-PA/K-PA nanoﬁbers to NGF, although it was statistically
insigniﬁcant, was translated to elevated cellular activity when
compared to control nanoﬁber systems (Figure 6). To test this,
unbound NGFs on HM-PA/K-PA nanoﬁber and control
surfaces were washed away, and bioactivity comparison was
performed only between bound NGFs. NGF-coated and
washed HM-PA/K-PA nanoﬁbers (50 ng/mL) lead to
signiﬁcantly longer neurites compared to E-PA/K-PA nanoﬁber
and PDL controls (Figure 6). There was no such diﬀerence
when 10 ng/mL NGF was used, which is in good correlation
with the results of growth factor binding analysis by ELISA
(Figure 6). In summary, HM-PA/K-PA nanoﬁbers interact with
NGF moderately and this interaction is translated into cellular
response without any loss in bioactivity of growth factor.
Promotion of the neurite length on HM-PA/K-PA nano-
ﬁbers is clearly dependent on HM-PA−NGF interaction that
could be translated to diﬀerentiation response upon induction
of cells by NGF activity. Immunostaining against β-III-tubulin,
a neuron-abundant microtubule protein, and synaptic protein
Synaptophysin 1 (Syn1) revealed higher expression of these
proteins when cells were cultured on HM-PA-NGF substrates
(Figure 7). Neural morphology was also more prominent on
this surface correlating with the longer neurites (Figure 6). β-
III-tubulin is a neuron-speciﬁc tubulin subunit that is
abundantly expressed along neurites as well as cell soma.26
Syn1 is a synaptic protein abundant in presynaptic nerve
terminal, and its presence along the axonal protrusions
indicates presynaptic nerve terminal development.27,28 Ex-
Figure 5. Results of neurite outgrowth assay on NGF treated substrates and NGF-free substrates. NGF coated in the above ﬁgure indicates that
substrates were treated with NGF without removal of unbound NGF on which cells were seeded. Soluble NGF indicates that cells cultured on NGF-
free substrates were induced with soluble NGF in culture media. NGF amounts used were 10 ng/mL (a) or 50 ng/mL (b). There was no signiﬁcant
diﬀerence for any substrate when coated NGF was compared with soluble NGF, except for HM-PA/K-PA and PDL at 10 ng/mL (*p < 0.05.
Statistical analysis was performed by using two-way ANOVA with Bonferroni posthoc analysis, n = 3).
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pression proﬁles of PC-12 cells cultured on HM-PA-NGF
substrate is consistent with the expected localization of these
neural marker proteins. β-III-tubulin was found to be localized
in cell soma along with neurites (Figure 7a). Cells also
expressed β-III-tubulin on E-PA/K-PA and PDL in cell soma
and in a few short neurites observed on E-PA/K-PA (Figure
7d,g). A dramatic diﬀerence in expression proﬁle of Syn1 was
found when cells were cultured on diﬀerent substrates, which
can be attributed to diﬀerential interaction of these surfaces
with NGF leading to diﬀerential cell responses (Figure 7b,e,h).
Syn1 expression was heavily concentrated along neurites and
nerve terminals on HM-PA/K-PA, while weak expression in cell
soma was observed on other substrates. Thus, it can be
concluded that higher level of binding of HM-PA to NGF
induces neural diﬀerentiation of PC-12 cells more eﬃciently,
leading to the formation of presynaptic nerve terminals, an
indicator of neural maturation, on this substrate.
4. CONCLUSION
In summary, the functionality of heparan sulfates in
extracellular matrix can be achieved synthetically through
presenting key functional groups of heparan sulfates on peptide
nanoﬁbers. While forming hydrogel scaﬀolds, these nanoﬁbers
bind to heparin-binding growth factors that are utilized
commonly in regenerative medicine studies and present them
Figure 6. Results of neurite outgrowth assay on NGF-treated
substrates. PDL and PA substrates were treated with 10 ng/mL or
50 ng/mL NGF after which they were washed to remove any unbound
NGF. HM-PA/K-PA interaction with NGF led to longer neurites on
this surface when 50 ng/mL NGF was used, probably due to higher
amount of NGF remaining on the HM-PA/K-PA nanoﬁber-coated
surface than E-PA/K-PA and PDL after washing (***p < 0.001
between HM-PA/K-PA and other surfaces at 50 ng/mL, *p < 0.05
between HM-PA/K-PA and E-PA/K-PA 2x or PDL, p > 0.05 between
HM-PA/K-PA and E-PA/K-PA at 10 ng/mL). Statistical analysis was
performed by using two-way ANOVA with Bonferroni posthoc
analysis (n = 3).
Figure 7. Immunostaining of PC-12 cells against β-III-Tubulin (a,d,g) and Syn1 (b,e,h) on NGF treated surfaces: (a−c) HM-PA/K-PA, (d−f) E-
PA/K-PA, (g−i) PDL. Panels c, f and i show merged images of Syn1 staining and β-III-Tubulin on the same cells. Higher expression of both neural
markers along with speciﬁc localization of Synaptophysin I in nerve terminals was clear in cells cultured on HM-PA/K-PA.
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to cells eﬀectively. Interestingly, for VEGF and FGF-2, this
binding speciﬁcally requires the presence of heparin-binding
domain of growth factors, which may be critical for proper
presentation of growth factors to cells. While we recently
reported angiogenesis and neural tissue engineering applica-
tions of these scaﬀolds,10,29 further work is underway for other
applications such as wound healing and bone and cartilage
tissue engineering.
■ ASSOCIATED CONTENT
*S Supporting Information
Additional AFM, ITC, and ELISA assay results. This material is
available free of charge via the Internet at http://pubs.acs.org.
■ AUTHOR INFORMATION
Corresponding Author
*Mailing Address: Institute of Materials Science and Nano-
technology, National Nanotechnology Research Center
(UNAM), Bilkent University, Ankara, TURKEY, 06800. E-
mail: atekinay@unam.bilkent.edu.tr (A.B.T.) and moguler@
unam.bilkent.edu.tr (M.O.G.). Tel: +90 312 290 3572 (A.B.T.)
and +90 312 290 3552 (M.O.G.). Fax: +90 312 266 4365.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
We would like to thank Z. Erdogan and Z. E. Ulger for their
technical help. This work was funded partially by Loreaĺ Young
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